跳转至内容
Merck
CN

PZ0383

Sigma-Aldrich

帕博昔利

≥98% (HPLC), powder, CDK 4 & 6 inhibitor

别名:

6-乙酰基-8-环戊基-5-甲基-2-[[[5-(1-哌嗪基)-2-吡啶基]氨基]吡啶基[2,3-d]嘧啶-7(8H)-酮, PD 0332991, PD 332991, PD-0332991, PD0332991, PD991, PF 00080665, PF-00080665, PF00080665, 爱博新

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C24H29N7O2
分子量:
447.53
UNSPSC代码:
12352200
NACRES:
NA.77

产品名称

帕博昔利, ≥98% (HPLC)

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

0.1 M HCl: 2 mg/mL, clear

储存温度

room temp

SMILES字符串

CC(C1=C(N2C3CCCC3)N=C(NC4=CC=C(N5CCNCC5)C=N4)N=C1)=C(C(C)=O)C2=O

InChI

1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)

InChI key

AHJRHEGDXFFMBM-UHFFFAOYSA-N

生化/生理作用

PF-00080665(Palbociclib;PD 0332991)是一种靶向周期蛋白依赖性激酶4&6(使用CDK4/cycD3、CDK4/cycD1、CDK6/cycD2的IC50分别为9、11、15 nM;靶向其他36种激酶的IC50为>10 μM)的口服活性且高度特异性的抑制剂,其可有效抑制Cdk4/6依赖性细胞Rb磷酸化过程(IC50 = 66 nM/pSer780 & 63 nM/pSer795; MDA-MB-435)。PF-00080665对Rb阳性的人乳腺癌/结肠癌/肺癌/白血病细胞具有选择性的抗增殖活性(IC50 = 40-400 nM;IC50 >3 μM/Rb阴性MDA-MB-468 & H2009),并且在体内显示出对小鼠多种晚期人类肿瘤异种移植物的有效(12.5-150 mg/kg/day p.o.)。

储存及稳定性

该化学品可以溶液形式在-80°C保存6个月,-20°C下1个月(避光)。

象形图

Health hazardEnvironment

警示用语:

Warning

危险分类

Aquatic Chronic 2 - Muta. 2 - Repr. 2 - STOT RE 2 Oral

靶器官

Bone marrow,male reproductive organs

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Shinya Kitamura et al.
Cancer science, 113(2), 802-807 (2021-12-07)
Extramammary Paget's disease (EMPD) is a rare adnexal neoplasm commonly seen in the genital areas among the senior population. The prognosis of advanced EMPD is not favorable; thus, the development of potential treatments has long been sought. Cyclin-dependent kinase (CDK)
Flora Doffe et al.
Cancers, 14(15) (2022-07-28)
The recent trend in 3D cell modeling has fostered the emergence of a wide range of models, addressing very distinct goals ranging from the fundamental exploration of cell-cell interactions to preclinical assays for personalized medicine. It is clear that no
ER
Angel L Guerrero-Zotano et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 24(11), 2517-2529 (2018-03-28)
E Martínez de Dueñas et al.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2018-03-23)
Cyclin-dependent kinases (CDKs) play a key role in cell cycle regulation, which makes them a clear therapeutic target to interfere with cell division and proliferation in cancer patients. Palbociclib, a specific inhibitor of CDK4/6 with outstanding clinical efficacy data and
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.
Daniele Cretella et al.
Journal of experimental & clinical cancer research : CR, 37(1), 72-72 (2018-03-29)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门